Drug intelligence / Profile preview

Re-Tain

Development stage: Discontinued
Lead developer: ImmuCell
Modality: Peptides
Administration: Intramammary

Overview

Re-Tain is a novel Nisin-based intramammary treatment developed by ImmuCell Corporation for subclinical mastitis in lactating dairy cows. It functions as a non-antibiotic alternative, aiming to treat mastitis without requiring a milk discard period, which addresses a significant economic concern in the dairy industry and aligns with regulatory efforts to reduce antibiotic use. The active pharmaceutical ingredient, Nisin, is a bacteriocin, a type of peptide.

Brand names: Re-Tain
Other names: Mast Out

Targets

Lipid II

Beyond the preview

Go deeper on Re-Tain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Re-Tain.

Explore the full profile